



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

4th August 2021

To,

Kruti Shah
On-Line Surveillance
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Dear Sir,

Re: Increase in Volume

This is in reference to your email dated August 04, 2021 vide reference no. L/SURV/ONL/PV/NK/2021-2022 / 252 regarding clarification for significant increase in the volume of security across exchanges, in the recent past.

We would like to clarify that the Company has made all the necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time and has not withheld any material information/ event that in our opinion would have a bearing on the operations/ performance of the Company which include all price sensitive information., etc.

The significant increase in the volume of the Company is likely to be purely market driven. We would like to reiterate that the Company will continue to comply with the listing regulations requirements and keep the Stock Exchange informed of all price sensitive information as and when they arise.

You are requested to please take the above clarification on record and keep the members of the exchange informed.

Thanking you,

Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
Company Secretary